PropertyValue
?:abstract
  • The pandemic coronavirus disease 2019 (COVID-19), caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rapidly spreading globally. Clinical observations found that systemic symptoms caused by SARS-CoV-2 infection are attenuated when using the anticoagulant agent heparin, indicating that heparin may play other roles in managing COVID-19, in addition to prevention of pulmonary thrombosis. Several biochemical studies show strong binding of heparin and heparin-like molecules to the Spike protein, which resulted in inhibition of viral infection to cells. The clinical observations and in vitro studies argue for a potential multiple-targeting effects of heparin. However, adverse effects of heparin administration and some of the challenges using heparin therapy for SARS-CoV-2 infection need to be considered. This review discusses the pharmacological mechanisms of heparin regarding its anticoagulant, anti-inflammatory and direct antiviral activities, providing current evidence concerning the effectiveness and safety of heparin therapy for this major public health emergency.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.carbpol.2020.117232
?:journal
  • Carbohydr_Polym
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/2afda8fb35e0508fa094e9b72c1755856714d722.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7581413.xml.json
?:pmcid
?:pmid
?:pmid
  • 33357843.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Comprehensive Landscape of Heparin Therapy for COVID-19
?:type
?:year
  • 2020-10-22

Metadata

Anon_0  
expand all